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Abstract: There is significant variation in reported associations of the MTHFR C677T
(rs1801133) and A1298C (rs1801131) polymorphisms and coronary artery disease
(CAD) in different global populations. This study aims to identify any individual or
combined associations between the 1298 and 677 loci of MTHFR and CAD in a North
Indian population. A total of 159 patients and 166 controls were genotyped using
validated TaqMan assays. Odds ratio analysis identified associations at crude level
and multiple logistic regression controlled for confounding variables. Linkage dis-
equilibrium between the loci was assessed along with haplotype association ana-
lysis. At the C677T locus, homozygosity of the T allele identified a significantly
protective association (OR = 0.38, CI: 0.24–0.60). For the A1298C locus the AC
genotype had a protective effect in codominant model (OR = 0.53, CI: 0.32–0.85)
and CC genotype showed a susceptible association in recessive model when con-
trolled for age, sex and lipids (OR = 2.70, CI: 1.27–5.77). This study identified that,
independently, both heterozygous genotypes show a protective association with
CAD. In addition the CC genotype of A1298C in recessive model was a susceptible
genotype. The combined associations of MTHFR are protective (primarily due to the
effects of C677T locus) suggesting an interaction between the loci and their asso-
ciations with CAD within this sample.
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1. Introduction
Cardiovascular diseases (CVDs) are currently the world’s number one killer, causing 17.7 million
deaths in 2015 and accounting for almost 31% of global deaths (World Health Organisation
[WHO], 2017). It encompasses a variety of circulatory diseases, most notably coronary artery
disease (CAD), which causes approximately 7 million deaths worldwide each year (Sharma et al.,
2014). Characterised by the progressive build-up of atherosclerotic plaques within the coronary
arteries, the disease is a result of myocardial ischemia causing the death of cardiac muscle tissue
and resulting in cardiac arrest and possible mortality. It has been estimated that the prevalence of
CAD within the population in India is currently around 10%. CAD is multifactorial and polygenic
with a range of genetic polymorphisms and their products contribute to disease inception, pro-
gression and severity.
Homocysteine is a homologue of the amino acid cysteine and is synthesised from methionine via
a multi-step process and has two primary fates, the conversion via tetrahydrofolate (THF) back into
methionine or conversion to cysteine. Homocysteine is involved in the promotion of platelet
activation, hypercoagulability, oxidative stress, endothelial dysfunction, smooth muscle prolifera-
tion and oxidation and peroxidation of lipids, all of which are associated with CVD via the athero-
sclerotic pathway (Refsum & Ueland, 1998). However, the full mechanisms for vascular damage
induced by hyperhomocysteinemia still remain unclear.
Methylenetetrahydrofolate reductase (MTHFR) is one of the main regulatory enzymes in the
metabolism of homocysteine that catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, the major circulatory form of folate in the body and a carbon donor for the
conversion of homocysteine to methionine in the remethylation pathway (Bailey and Gregory
1999). With the impaired function of the enzyme, plasma total homocysteine (tHcy) is able to
increase to a point at which it becomes an independent risk factor for CAD. Reduced activity of the
enzyme can lead to increased levels of plasma tHcy, resulting in hyperhomocysteinemia (HHcy).
The association between HHcy levels and CAD has been found to vary in different populations
following different dietary practices, smoking, and inhabiting different environmental conditions.
There was no significant association identified in Southern (Deepa et al., 2001; Sastry et al., 2001)
or Western India (Nair, Nair, Ashavaid, Dalal, & Eghlim, 2002), whereas a study from the UK
(Chambers et al., 2000) and Northern India (Khare, Ghosh, Shetty, Kulkarni, & Mohanty, 2004;
Puri et al., 2003) found HHcy to be significantly associated with CAD. Furthermore, evidence
suggests that a 10% increase in homocysteine levels can be matched by the increased risk of
CAD (Varga, Sturm, Misita, & Moll, 2005).
The MTHFR gene situated on the short branch of chromosome 1 (1p36.3) encodes for MTHFR
enzyme and consists of ~17 kb, which include 11 exons spanning 2.2 kb (Goyette et al., 1998). A
total of 34 rare mutations in the MTHFR gene, as well as a total of 9 common variants have been
reported in studies examining MTHFR deficiency (Goyette et al., 1998). The common variants
include: C677T (rs1801133), A1298C (rs1801131) and ARG184TER (rs121434294).
The MTHFR C677T transition is a missense mutation in the exon 4 of this gene. This converts an
alanine to a valine at codon 222 in the N-terminal catalytic domain of the protein leading to a
thermolabile protein, with decreased enzymatic activity (Unfried et al., 2002). The T allele mod-
ulates the levels of hyperhomocysteinemia and cardiovascular risk in different populations. Some
studies have reported direct effect of this allele on homocysteine levels in European and other
populations (Gudnason et al., 1998; Huang et al., 2011; Pitsavos et al., 2006) while others report no
associations (Chambers et al., 2000) primarily due to the influence of various dietary and environ-
mental factors. Chambers et al. (2000) found that homocysteine levels among Indians living in the
UK, showed no association with MTHFR-T allele, which was partially explained by low folate and
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vitamin B12 levels, highlighting that MTHFR-homocysteine-CAD associations may be influences by
various dietary, environmental, ethnic and other factors, including gene-gene, gene-environment
interactions. Some studies have documented the T allele to be significantly higher in CAD patients
than controls (Dhar et al., 2010; Ezzat et al., 2014; Falchi et al., 2005; Ghazouani et al., 2009; Sinha
et al., 2010; Vinukonda, Mohammad, Jain, Chintakindi, & Akella, 2009; Yu et al., 2014).
Homozygosity of the T allele at the 677 locus has been found to be causal in some studies,
while many studies identified heterozygosity to be significantly causal (Dhar et al., 2010; Ezzat
et al., 2014; Freitas et al., 2008; Ghazouani et al., 2009; Sinha et al., 2010).
The second mutation in MTHFR A1298C is a point mutation in exon 7. This transversion causes a
glutamate to alanine substitution at codon 429, within the C-terminal regulatory domain of the
protein (Ananth et al., 2007). This polymorphism also causes a reduction in MTHFR activity,
although its effect is considered to be less than that conferred by the C677T transition (Le
Marchand, Wilkens, Kolonel, & Henderson, 2005). The differences in levels of attenuation conferred
by the different polymorphisms have been investigated in some studies, which postulate that the
C677T and A1298C polymorphisms reduce the activity of MTHFR by 60% and 35%, respectively
(Sinha et al., 2010).
The A1298C polymorphism is less well documented, with variable association results in different
populations. Much of the research into the area suggests that the variant “C” allele is associated
with higher levels of CAD (Kumar et al., 2005; Sinha et al., 2010; Szczeklik et al., 2001). However,
other studies have found 1298AA genotype (Freitas et al., 2008) and 1298AC genotype (Laraqui
et al., 2007; Sinha et al., 2010) to be associated with CAD. Few studies have combined the two loci;
however, it has been shown that the combined additive effect of homozygosity in both the C677T
and A1298C loci leading to significantly higher levels of plasma tHcy in the Portuguese population
(Castro et al., 2004). Heterozygosity at both loci was found to be significantly causal in Portuguese
(Freitas et al., 2008) and Tunisian (Ghazouani et al., 2009) populations.
The aims of the current study were to document the genetic variation of MTHFR C677T and
A1298C loci and evaluate genetic associations with CAD in a well characterised North Indian
population.
2. Methods
The study population consisted of 166 healthy controls and 159 patients with diagnosed CAD, from
Uttar Pradesh, North India. Patients were classified on the basis of at least 50% or more stenosis in
one or more coronary arteries, verified through coronary angiography. The healthy controls had no
known history of ischemic heart disease, hypertension, diabetes, endocrine or metabolic disorders
and were selected after administering a treadmill test to exclude the possibility of the patients
having an underlying CAD (Rai, Sinha, Finn, Agrawal, & Mastana, 2016; Rai et al., 2012). The DNA
samples were collected with full written consent and study protocol was approved by SGPGIMS
Lucknow ethics committee and Loughborough University. Clinical data was gathered on: age,
gender, diet (vegetarian vs. non-vegetarian), smoking-status and lipid profiles (plasma total cho-
lesterol (TC), triglycerides (TG), high-density lipoproteins (HDL), low-density lipoproteins (LDL), very-
low-density lipoproteins (VLDL) and apolipoprotein B (ApoB)). DNA extraction was done through
the use of organic methods, as detailed in Rai et al. (2012).
MTHFR C677T (rs1801133) and A1298C (rs1801131) polymorphisms were genotyped by sensitive
TaqMan® SNP Genotyping kits (Assay IDs C_1202883_20 and C_850486_20 respectively) on
StepOne Plus QPCR machine (Applied Biosystems).
Statistical analysis was carried out using the computer packages EXCEL and SPSS (version
21.0). The patient and control databases were both assessed for Hardy–Weinberg Equilibrium
(HWE) by calculating a chi-square value. Association statistics like odds ratios (OR) associated
confidence intervals and p values were calculated using online programme called SNPSTATs
Butler et al., Cogent Medicine (2018), 5: 1478477
https://doi.org/10.1080/2331205X.2018.1478477
Page 3 of 11
(http://bioinfo.iconcologia.net/SNPstats) (Solé, Guinó, Valls, Iniesta, & Moreno, 2006). Clinical and
life style parameters were analysed using a Kruskal-Wallis test. A P value <0.05 was considered
statistically significant (for the analysis of two SNPs, significant p value of 0.025 was used).
SNPstats programme was also used for adjustments for various confounding parameters and
calculation of linkage disequilibrium and construction of haplotypes.
Sample size was calculated using Quanto’ software (http://biostats.usc.edu/Quanto.html), which
allowed an estimation of a required sample size of 153 patients and 153 controls to achieve an OR
of 1.5 and above at 80% power. As the genotyping was blinded, 19 (6 patients and 13 controls)
extra samples were analysed to allow for any failures or missing data points. Overall success rate
for both loci was 96.7%.
3. Results
Analysis of the clinical data through a Kruskal-Wallis test (Table 1) identified a significant difference in
age and all lipid parameters. To control for these differences adjustedORwere calculated in addition to
crude OR. HWE was violated in controls for C677T locus (P < 0.001), therefore these results should be
considered with caution. Allele frequencies and genotype distribution of controls were compared with
1000 genomeand Indian populations (IGSR;Saraswathy et al., 2012; Sinha et al., 2010). At C677T locus,
T allele in current control group (33%) is higher than observed in 1,000 Genome South Asian popula-
tions (8.3–15%, average 12%) but comparable to many European populations (27–46%). At A1298C
locus (rs1801131), genotype and allele frequencies showed no differences (40% vs. 42%).
At the C677T locus (rs1801133), significant differences were noticed in heterozygosity when
comparing controls versus patients (56.0% and 34.6%, respectively). TT genotype frequency
was low in both groups, while CC genotype was more frequent in patients (63.5%) compared
to controls (39.2%). Overall, there was a significant difference between patients and controls
(chi-square 19.69, 2df, P< 0.001). At the A1298C locus (rs1801131), again, there was lower
level of heterozygosity in patients compared to controls (35.9% vs. 53.0%) and higher
frequency of both homozygotes. This led to significant differences between the two groups
(10.03, 2df, P< 0.01).
The ORs were calculated using codominant, recessive and log-additive (allelic) models at
crude level and with adjustments for clinical parameters (age, sex and lipids) and the results
are given in Table 2. At the C677T locus, CT and TT genotypes in codominant mode show
statistically significant protective effects (OR = 0.38 (CI 0.24–0.60, P < 0.001) and OR = 0.24
(CI 0.06–0.94, P < 0.001)) and these effects were stronger when adjustments were made for
age, sex and lipid parameters. A similar protective effect is observed in log additive/allelic
model but the recessive model showed a non-significant effect. Caution is warranted as the
number of TT genotypes observed in the study is relatively low and the control population is
not in HWE.
At A1298C locus, it is evident that heterozygosity provides a significant protection from CAD
with an OR of 0.53 (CI: 0.32–0.85, P < 0.01) when compared to an AA genotype, which
remains significant after adjustments (OR = 0.49, CI:0.25–0.93, P < 0.01). The variant CC
genotype shows susceptible effect with odd ratios of 1.71 (CI: 0.95–3.09, P = 0.07) in crude
recessive model and is statistically significant when adjusted for age, sex and lipids
(OR = 2.70 (CI: 1.27–5.77, P = 0.008)).
Haplotypes were constructed using SNPStats programme; patients had a relatively higher fre-
quency of C/C haplotype (C677T/A1298C) (44.7% vs. 31.0%) (Table 1) while controls had a higher
frequency of T/A haplotype (29.9% vs. 16.7%) leading to protective associations in all combinations
(Tables 1 and 2). Linkage disequilibrium Dʹ statistics was of medium range (Dʹ = 0.684) but
statistically significant (P < 0.001).
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Genotype-wise analysis of lipids and other parameters did not reveal any significant pattern for
both loci (results not shown) but MTHFR genotype combinations (Diplotypes) were also evaluated
for genetic associations in crude model and results are given in Table 3. It is clear from Table 3 that
combination of heterozygous genotypes, 677CT/1298CA, protects against CAD in this sample
(OR = 0.14, CI: 0.06–0.32, P < 0.001). Further analysis using a Kruskal-Wallis test identified that
the presence of a CT/CA diplotype versus a CC/AA diplotype was associated with a significantly
lower HDL (P = 0.003), LDL (P = 0.027) and TC (P = 0.046) levels.
Table 1. Descriptive statistics of clinical data and summary of genotyping results
Parameter (SI) Patients n = 159
(Mean ± SD)
Controls n = 166
(Mean ± SD)
P Value
Age (Years) 48.72 ± 11.87 44.55 ± 13.79 0.004*
Gender (Male/Female) 137/22 137/29 0.55
Smokers (Yes/No) 98/61 90/76 0.15
Diet (Non Veg/Veg 91/68 85/81 0.22
S.TC (mg/dL) 175.50 ± 53.11 136.05 ± 31.41 <0.001*
S.TG (mg/dL) 201.71 ± 91.42 138.49 ± 59.12 <0.001*
S.HDL (mg/dL) 31.78 ± 9.29 27.10 ± 9.75 <0.001*
S.LDL (mg/dL) 103.26 ± 46.90 82.08 ± 24.53 <0.001*
S.VLDL (mg/dL) 41.63 ± 16.95 28.55 ± 12.16 <0.001*
ApoB (mg/dL) 147.97 ± 46.70 104.28 ± 44.93 <0.001*
C677T Genotype Frequencies (n (%))
CC 101 (63.5%) 65 (39.2%)
CT 55 (34.6%) 93 (56.0%)
TT 3 (1.9%) 8 (4.8%)
HWE p value 0.15 0.001^
Allele Frequencies ± SE
C 0.81 ± 0.02 0.67 ± 0.03
T 0.19 ± 0.03 0.33 ± 0.03
Patients vs. Controls: Chi-square and p value: 19.69, 2DF, P value <0.001
A1298C Genotype Frequencies (n (%))
AA 69 (43.4%) 56 (33.7%)
CA 57 (35.9%) 88 (53.0%)
CC 33 (20.8%) 22 (13.3%)
HWE p value 0.002^ 0.17
Allele Frequencies ± SE
A 0.61 ± 0.03 0.60 ± 0.03
C 0.39 ± 0.03 0.40 ± 0.03
Patients vs. Controls: Chi-square and p value: 10.03, 2DF, Pvalue = 0.007
Observed Haplotype Frequencies C677T/A1298C %
C/A 44.7 31.0
C/C 36.2 36.2
T/A 16.7 29.3
T/C 2.5 3.6
Dʹ statistics = 0.684; p value <0.001.
*T-test or non-parametric test p values. All P values are quoted to a maximum of 3 d.p.
^Significant departure from Hardy-Weinberg equilibrium.
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4. Discussion
The dissimilarity in allele frequencies between the patients (19%) and controls (33%) for the variant T
allele, at position 677 (rs1801133), suggests this allelemay have aCADprotective effect. This findingwas
further confirmed by the OR and associated confidence intervals in various combinations (crude and
adjusted) where T allele and CT and TT genotypes are observed to be protective with OR values lower
than 1. This conclusion differs from some previous studies proposing the T allele as causal (Dhar et al.,
2010; Ezzat et al., 2014; Falchi et al., 2005; Ghazouani et al., 2009; Sinha et al., 2010; Vinukonda et al.,
2009; Yu et al., 2014). One possibility for this apparent divergence could be due to the low number of TT
genotypes observed in this study and departure from HWE in controls, so caution is required in inter-
pretations here. That said, the association of the T allele (C677T (rs1801133)) with CAD is currently
inconsistently reported with both causal and protective roles proposed (Wald, Law, & Morris, 2002; Zee
et al., 2007). Ameta-analysis of 80 studies has given an estimate of a 14%greater risk of CAD associated
with the CC genotype (Lewis, Ebrahim, & Davey Smith, 2005), which supports our study illustrating an
Table 2. Crude and adjusted odds ratios for MTHFR C677T and A1298C loci among CAD
patients and controls
Odds ratios
Model Genotype/Allele Crude Adjusted for age, sex
and lipids
C677T (n = 325)
CC 1 (Ref) 1 (Ref)
Codominant CT 0.38 (0.24–0.60)* 0.34 (0.19–0.61)*
TT 0.24 (0.06–0.94)* 0.16 (0.03–.92)*
P Value <0.001* 0.001*
Recessive CC+CT 1 (Ref) 1 (Ref)
TT 0.38 (0.10–1.46) 0.26 (0.05–1.49)
P value 0.14 0.09
Log additive T* 0.41 (0.27–0.61)* 0.35 (0.21–0.60)*
P value <0.001* 0.001*
A1298C (n = 325)
AA 1 (Ref) 1 (Ref)
Codominant AC 0.53 (0.32–0.85)* 0.49 (0.25–0.93)*
CC 1.22 (0.64–2.32) 1.84 (0.80–4.22)
P value 0.01* 0.003*
Recessive AA-AC 1 (Ref) 1 (Ref)
CC 1.71 (0.95–3.09) 2.70 (1.27–5.77)*
P value 0.07 0.008*
Log additive C* 0.96 (0.71–1.30) 1.15 (0.77–1.70)
P value 0.78 0.50
Haplotype association analysis C677T and A1298C (n = 325)
C/A 1 (Ref) 1 (Ref)
C/C 0.71 (0.49–1.05) 0.80 (0.49–1.31)
T/A 0.34 (0.21–0.56)* 0.29 (0.16–0.56)*
T/C 0.36 (0.11–1.18) 0.35 (0.08–1.48)
P value <0.001 <0.001
Global Haplotype
association P value
<0.001* <0.001*
*Chi-square P values, quoted to a maximum of 3 d.p.
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increased suseptibility with the CC genotype (OR = 4.14 (CI = 1.06–16.19)) and the ancestral C allele
(OR = 2.09 (CI = 1.44–2.96)).
The overall low frequency of the TT genotype (C677T (rs1801133)) in this study (patients 1.9%
and controls 4.8%) is comparable to results from 23 populations from different parts of India
where TT genotype frequency and T allele frequency are also low (Saraswathy et al., 2012). A
significantly higher incidence of the TT genotype has been reported in an Eastern Indian study
(patients 26.7% and controls 12.9%; Dhar et al., 2010), yet it is anticipated that this simply reflects
geographical variation (Saraswathy et al., 2012). The TT genotype would be expected to be more
frequent among patients as it is likely to be more deleterious (Sinha et al., 2010), however, the
current study shows a slightly higher frequency among controls. This may be due to the small
sample size but Sinha et al. (2010) suggest that the control individuals with TT genotypes coupled
with favourable biochemical markers are able to survive, whereas TT patients are in survival
disadvantage with unfavourable biochemical markers (high TG and LDL) and thus being selected
against.
The similarity in allele frequencies for MTHFR A1298C (rs1801131) between the patients and
controls suggests that in this population there is no significant CAD association. This is further
reinforced by the crude OR analysis with an OR close to 1 being observed (0.96 (CI: 0.71–1.31)
refer Table 2). The overall spectrum of observed variation for the C allele was similar to other
Indian and 1,000 genome populations (1,000 genome; Saraswathy et al., 2012), but it should
be noted that these were higher than observed in European populations (Freitas et al., 2008;
Kölling et al., 2004).
Genotype frequencies for MTHFR A1298C (rs1801131) differed between cases and controls,
with key differences being in the higher proportion of homozygosity in patient’s (Table 1). The
observed genotypes identified in this study differ from previous studies, which report lower
proportions of homozygosity at MTHFR A1298C (rs1801131) in different populations (Freitas
et al., 2008; Kölling et al., 2004; Sinha et al., 2010). The observed homozygosity of the MTHFR
A1298C variant allele appeared to increase the CAD susceptibility (Table 2) but this associa-
tion did not attain statistical significance in the codominant model for crude or adjusted
analyses. In the recessive model (CC vs. AA + AC), the effect was higher in crude analysis
(OR = 1.71, CI 0.95–3.09), and remained statistically significant when adjusted for age, sex
and lipids (OR = 2.57, CI 1.22–5.45). The heterozygous genotype AC showed a CAD protective
effect in all analyses (Table 2) that would support the recessive nature of homocystinuria
(Mandava & Kent, 2017). The key loci effect apears to lie in heterozygosity, Freitas et al.
Table 3. Combined analysis of MTHFR C677T and A1298C genotypes
Genotype
combinations
(C677T/A1298C)
Odds ratio 95% confidence
intervals
Chi-square P-Value*
CC/AA 1.00 Reference
CC/AC 0.38 0.17–0.83 5.12 0.024
CC/CC 0.69 0.28–1.69 0.33 0.564
CT/AA 0.33 0.15–0.73 6.65 0.010
CT/CA 0.14 0.06–0.32 22.23 <0.001
CT/CC 0.27 0.07–0.99 2.93 0.087
TT/AA 0.14 0.03–0.61 6.24 0.012
TT/AC NA
TT/CC NA
*Chi-square P value, quoted to 3 d.p.
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(2008) and Janošíková et al. (2003) have also identified CAD protective implications of
heterozygosity in Portuguese and Czech populations respectively. Yet, no clear trend in the
effect of the locus on the activity of MTHFR is seen in areas, such as Tunisia (Ghazouani et al.,
2009), Poland (Szczeklik et al., 2001) and Delhi (Sinha et al., 2010) where heterozygosity
appears to have a potentially causal effect.
Independently, both C677T and A1298C polymorphisms displayed heterozygosity as significantly
protective (Table 3). It is proposed that with the addition of the heterozygous 677CT genotype to each
of the 1298 genotypes the nature of the combined genotype becomes increasingly protective (Table 3).
The heterozygous combination, CT/CA, presented the highest significance with a protective nature
(p < 0.001) due to a potentially interactive relationship however; combining the two most causal
genotypes did not have the same effect. This would suggest that the allelic composition, in particular
the 677 alleles, influences the overall interaction of the loci and their association with CAD. Kruskal-
Wallis testing identified that the presence of a CT/CA genotype versus a CC/AA was associated with a
significantly lowerHDL (P= 0.003), LDL (P = 0.027) and TC (P= 0.046). This suggests that the pathogenesis
of the combined genotypes; resulting in protective and causal natures, involve HDL, LDL and TC, which
are extremely important risk factors for CAD. This points towards a relation of other potential confound-
ing variables (diet, dietary fats, smoking, etc.) with causation of CAD and thus it could be considered that
the MTHFR polymorphisms are not independent risk factors for CAD in the present population.
It has been suggested that the C677T mutation can decrease the enzymatic activity of
MTHFR enzyme by almost 60% and that the A1298C mutation could decrease the enzymatic
activity by about 35%. There is a highly significant (P < 0.001) protective association for the T/
A haplotype at crude (OR = 0.34, CI: 0.21–0.56) and adjusted models (OR = 0.30, CI: 0.16–0.57,
P < 0.001) (Table 2). Comparably, Sinha et al. (2010) showed the T/A haplotype to be
protective with a similar OR suggesting that the C677T mutation when combined with the
wild-type 1298A allele is protective within an Indian population. However, in the Portuguese
(Freitas et al., 2008) and Tunisian (Ghazouani et al., 2009) populations, a significant causal
association was identified for the T/A haplotype with an OR of 1.24 (CI: 1.00–1.54) and 2.35
(CI: 1.62–3.38), respectively, illustrating ethnic differences.
Few recent studies have attempted to compare C677T and A1298C genotype distributions
between CAD patients and controls (Alam et al., 2007; Bennouar et al., 2007; Freitas et al.,
2008). Different samples sizes and different ethnic backgrounds mean the studies are non-
contiguous, however these studies agree when reporting a significant association between
677TT genotype and hyperhomocysteinemia. However, only one of the studies found a sig-
nificant association with CAD (Bennouar et al., 2007), potentially proposing population speci-
ficity of the CAD hyperhomocysteinemia association. It is reported that the expression of
MTHFR mutations is both Vitamin B12 and folate dependent (Yajnik et al., 2006), so, it could
be suggested that the C677T polymorphism is only associated with an increased risk of CAD
when compounded by low Vitamin B12 and/or folate (Klerk et al., 2002). Folic acid deficiency
may be relatively uncommon in Indians compared to the western world mainly due to their
principally vegetarian diet but a high prevalence of Vitamin B12 deficiency is reported among
Indians (Sinha et al., 2010; Yajnik et al., 2006). As Vitamin B12 is responsible for metabolising
folic acid, its deficiency in the diet alone is likely to cause hyperhomocysteinemia due to un-
metabolised folic acid, thereby increasing the risk of CAD (Sinha et al., 2010). So, the differing
associations found between C677T polymorphism and CAD are potentially mediated through
Vitamin B12 deficiency, thus, supplementation could be recommended for those individuals
carrying causal alleles as a protective step predisposing to CAD.
In conclusion, further study with a larger sample size, including the assessment of vitamin
status, amongst other confounding variables, such as hypertension and plasma homocysteine
levels, to better clarify the relationship between MTHFR genotypes and CAD in various Indian
populations is warranted.
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